西地尼布的临床药代动力学与药效学
西地尼布强效选择性抑制VEGFR-1、-2和-3,20mg/天对卵巢癌有效。本综述汇总其PK特征:高脂餐降低AUC 24%和Cmax 33%,蛋白结合约95%,0.5-60mg剂量范围内PK线性,主要经粪便排泄,t1/2约22h。CYP3A4强抑制剂酮康唑使AUCss增加21%,强诱导剂利福平降低39%。轻中度肝肾功能不全、年龄和体重无需调整剂量,未见QTc显著延长。
要点
- 高脂餐降低西地尼布AUC 24%和Cmax 33%,建议空腹服用。
- 酮康唑增加AUCss 21%,利福平降低39%,注意P-gp介导的相互作用。
- 轻中度肝肾功能不全、年龄和体重无需调整剂量。
核心结论
- 西地尼布20mg/天对卵巢癌有效,PK呈线性,主要经粪便排泄。
- 强P-gp抑制剂/诱导剂可显著改变西地尼布暴露,需关注相互作用。
研究设计与样本
- 综述汇总西地尼布临床药代动力学与药效学研究。
主要发现
- 高脂餐降低西地尼布AUC 24%、Cmax 33%。
- 西地尼布血浆蛋白结合约95%,主要结合白蛋白和α1-酸性糖蛋白。
- 0.5-60mg剂量范围内AUC和Cmax随剂量成比例增加,PK呈线性。
- 西地尼布经FMO1、FMO3和UGT1A4代谢,粪便排泄占59%,尿中原型药<1%。
- 平均终末半衰期22h,表观口服清除率中等。
关键数值与推荐
- 酮康唑使西地尼布AUCss增加21%,利福平降低39%。
- 轻中度肝肾功能不全无需调整剂量,年龄和体重无需调整剂量。
- 0.5-60mg剂量汇总分析未见QTc间期显著延长。
- 血压升高和腹泻发生率与西地尼布剂量及全身暴露增加相关。
临床怎么用
- 西地尼布建议空腹服用,避免高脂餐影响吸收。
- 合用强P-gp抑制剂或诱导剂时需评估西地尼布暴露变化。
- 轻中度肝肾功能不全、老年及不同体重患者无需调整剂量。
- 用药期间监测血压和腹泻,警惕剂量及暴露相关不良反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cediranib potently and selectively inhibits all three vascular endothelial growth factor receptors (VEGFR-1, -2 and -3), and clinical studies have shown that it is effective in patients with ovarian cancer at a dose of 20 mg/day. Cediranib is absorbed moderately slowly; a high-fat meal reduced the cediranib area under the plasma concentration-time curve (AUC) by 24% and maximum plasma concentration (C max) by 33%. Cediranib binds to serum albumin and α1-acid glycoprotein; protein binding in human plasma is approximately 95%. The cediranib AUC and C max increase proportionally with dose from 0.5 to 60 mg, and cediranib has linear pharmacokinetics (PK) over time. Cediranib is metabolized via flavin-containing monooxygenase 1 and 3 (FMO1, FMO3) and uridine 5'-diphospho-glucuronosyltransferase (UGT) 1A4. Cediranib and its metabolites are mainly excreted in faeces (59%), with <1% of unchanged drug being excreted in urine. The apparent oral clearance is moderate and the mean terminal half-life is 22 h. Cediranib is a substrate of multidrug resistance-1 (MDR1) protein (also known as P-glycoprotein [P-gp]). Coadministration with ketoconazole, a potent P-gp inhibitor, increases cediranib AUC at steady-state (AUCss) in patients by 21%, while coadministration with rifampicin, a potent inducer of P-gp, decreases cediranib AUCss by 39%. Administration of cediranib with chemotherapies demonstrated minimal PK impact on each other. No dose adjustment is recommended for patients with mild or moderate hepatic or renal impairment, and no dose adjustment is needed on the basis of age and body weight. A pooled analysis at doses of 0.5-60 mg showed no significant increase in QTc intervals. Increases in blood pressure and the incidence of diarrhoea were associated with increased cediranib dose and systemic exposure.
引用
- Tang W, McCormick A, Li J, et al. Clinical Pharmacokinetics and Pharmacodynamics of Cediranib. Clin Pharmacokinet. 2017. PMID: 27943222. doi:10.1007/s40262-016-0488-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。